Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8:65–124.

CAS  PubMed  Article  Google Scholar 

Shamsuddin AKM, Quinton PM. Concurrent absorption and secretion of airway surface liquids and bicarbonate secretion in human bronchioles. Am J Physiol Lung Cell Mol Physiol. 2019;316:L953–60.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, et al. Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem. 2021;213:113195.

CAS  PubMed  Article  Google Scholar 

Terlizzi V, Tosco A, Tomaiuolo R, Sepe A, Amato N, Casale A, et al. Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. J Cyst Fibros. 2014;13:579–84.

CAS  PubMed  Article  Google Scholar 

Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C, et al. Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm Med. 2018;18:196.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Marson FAL. Disease-modifying genetic factors in cystic fibrosis. CurrOpinPulm Med. 2018;24:296–308.

CAS  Google Scholar 

Sofia VM, Surace C, Terlizzi V, Da Sacco L, Alghisi F, Angiolillo A, et al. Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with Cystic Fibrosis. MolMed. 2018;24:38.

Google Scholar 

Terlizzi V, De Gregorio F, Sepe A, Amato N, Arduino C, Casale A, et al. Brand new SPINK1 and CFTR mutations in a child with acute recurrent pancreatitis: a case report. Minerva Pediatr. 2013;65:669–72.

CAS  PubMed  Google Scholar 

Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, et al. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. J Cyst Fibros. 2017;16:207–13.

PubMed  Article  Google Scholar 

Taccetti G, Botti M, Terlizzi V, Cavicchi MC, Neri AS, Galici V, et al. Clinical and genotypical features of false-negative patients in 26 years of Cystic Fibrosis neonatal screening in Tuscany, Italy. Diagnostics (Basel). 2020;10:446.

CAS  Article  Google Scholar 

Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016;4:653–61.

PubMed  Article  Google Scholar 

Super M. Cystic fibrosis newborn screening and detection of carriers. Arch Dis Child Fetal Neonatal Ed. 2003;88:F448–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J, et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and Cystic Fibrosis screen positive, inconclusive diagnosis. J Pediatr. 2017;181S:S45–511.

PubMed  Article  Google Scholar 

Barben J, Castellani C, Munck A, Davies JC, de Winter-de Groot KM, Gartner S, et al. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). J Cyst Fibros. 2020;S1569–1993(20):30909–17.

Google Scholar 

Terlizzi V, Claut L, Tosco A, Colombo C, Raia V, Fabrizzi B, et al. A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. J Cyst Fibros. 2021;20:828–34.

CAS  PubMed  Article  Google Scholar 

LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr, Cystic Fibrosis Foundation. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr. 2007;151:85–9.

PubMed  Article  Google Scholar 

Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of Cystic Fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4-S15.e1.

PubMed  Article  Google Scholar 

Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10(Suppl 2):S86-102.

CAS  PubMed  Article  Google Scholar 

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a single Phe508del Allele. N Engl J Med. 2019;381:1809–19.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Medio P, Ferrillo L, et al. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Respir Med. 2021;189:106646.

PubMed  Article  Google Scholar 

Cabral B, Terlizzi V, Laselva O, Conte Filho C, Mota F. Anticipating new treatments for Cystic Fibrosis: a global survey of researchers. J Clin Med. 2022;11:1283.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Guerra L, Favia M, Di Gioia S, Laselva O, Bisogno A, Casavola V, et al. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Expert Opin Drug Discov. 2020;15:873–91.

CAS  PubMed  Article  Google Scholar 

Suri R. The use of human deoxyribonuclease (rhDNAse) in the management of cystic fibrosis. BioDrugs. 2005;19:135–44.

CAS  PubMed  Article  Google Scholar 

Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest. 2005;128:2327–35.

CAS  PubMed  Article  Google Scholar 

Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;9:CD001127.

PubMed  Google Scholar 

Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA. 1968;205:312–3.

CAS  PubMed  Article  Google Scholar 

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17:153–78.

PubMed  Article  Google Scholar 

Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680–9.

PubMed  Article  Google Scholar 

Cystic Fibrosis Foundation Patient Registry Annual Data Report 2020. https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf.

European Cystic Fibrosis Society Patient Registry Annual Data Report 2019. https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report_2019_v1_23Dec2021.pdf.

Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637–42.

CAS  PubMed  Article  Google Scholar 

Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison ofhypertonic saline and alternate-day or daily recombinant human deoxyribonucleasein children with cystic fibrosis: a randomised trial. Lancet. 2001;358:1316–21.

CAS  PubMed  Article  Google Scholar 

Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2021;3:CD007923.

PubMed  Google Scholar 

McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease Pulmozyme Study Group. Chest. 1996;110:889–95.

CAS  PubMed  Article  Google Scholar 

Frederiksen B, Pressler T, Hansen A, Koch C, Høiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006;95:1070–4.

PubMed  Article  Google Scholar 

Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139:813–20.

CAS  PubMed  Article  Google Scholar 

Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et al. Bronchoalveolar lavage for the evaluation of antiinflammatory treatment study group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med. 2004;169:719–25.

PubMed  Article  Google Scholar 

Newsome SJ, Daniel RM, Carr SB, Bilton D, Keogh RH. Investigating the effects of long-term dornase alfa use on lung function using registry data. J Cyst Fibros. 2019;18:110–7.

CAS  PubMed  Article  Google Scholar 

Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, dailyrhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax. 2010;65:51–6.

CAS  PubMed  Article  Google Scholar 

AdemhanTural D, Yalçın E, Emiralioglu N, Ozsezen B, Sunman B, NayirBuyuksahin H, et al. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis. Pediatr Pulmonol. 2022;57:142–51.

Article  Google Scholar 

Terlizzi V, Masi E, Francalanci M, Taccetti G, Innocenti D. Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice. Ital J Pediatr. 2021;47:168.

PubMed  PubMed Central  Article  Google Scholar 

Mainz JG, Schien C, Schiller I, Schädlich K, Koitschev A, Koitschev C, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst

留言 (0)

沒有登入
gif